Publications
1,282
Citations
73,806
Est. group size
~17
Recurring co-author estimate
Active years
48
Publishing since 1979
Typically publishes in teams of ~19 · 2% small-team papers (≤3 authors) · across 43 venues
- Activity of PROTAC MDM2 degrader in primary leukemia cells and PDX models
Leukemia · 2026
- From fatal disease to functional cure: 25 years of tyrosine kinase inhibition in chronic myeloid leukemia
Leukemia · 2026
- RALLY-MF: Initial efficacy of a phase 2 study of DISC-0974, an anti-hemojuvelin antibody, to treat anemia in myelofibrosis.
Journal of Clinical Oncology · 2026
- NCCN Guidelines® Insights: Myeloproliferative Neoplasms, Version 2.2026
Journal of the National Comprehensive Cancer Network · 2026
- Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trial
Nature Medicine · 2025
- Asciminib monotherapy in patients with chronic myeloid leukemia in chronic phase without BCR::ABL1T315I treated with at least 2 prior TKIs: Phase 1 final results
Leukemia · 2025
- Understanding the Functional Dependence and Inhibition of the Bcl-2 Pro-Survival Proteins in a Wide Spectrum of Cancers toward Precision Medicine
ACS Pharmacology & Translational Science · 2025
- A deep learning aided bone marrow segmentation of quantitative fat MRI for myelofibrosis patients
Frontiers in Oncology · 2025
- A phase 2 study of itacitinib alone or in combination with low-dose ruxolitinib in patients with myelofibrosis
Leukemia Research · 2025
- Time Without Transfusion Reliance (TWiTR): Integrating Survival Quality Into Myelofibrosis Treatment Strategies Based on the Phase 3 SIMPLIFY‐1, SIMPLIFY‐2, and MOMENTUM Trials
eJHaem · 2025
- Durable efficacy and long-term safety with pelabresib plus ruxolitinib in JAK Inhibitor–Naive myelofibrosis: 96-week Results from the Phase III MANIFEST-2 study
Blood · 2025
- ALL-724: First-in-Human Study of Asciminib Monotherapy in Adults With Relapsed/Refractory (R/R) Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
Clinical Lymphoma Myeloma & Leukemia · 2025
- MPN-757: A Phase 1b Trial of DISC-0974, an Anti-Hemojuvelin Antibody, in Patients With Myelofibrosis and Anemia
Clinical Lymphoma Myeloma & Leukemia · 2025
- RALLY MF: A phase 2 Study of DISC-0974, an anti-hemojuvelin antibody, in patients with myelofibrosis and anemia
Blood · 2025
- Effects of Calreticulin Mutations on HLA Class I Expression in Myeloproliferative Neoplasms
bioRxiv (Cold Spring Harbor Laboratory) · 2025
- Blood×85
- Clinical Lymphoma Myeloma & Leukemia×71
- HemaSphere×23
- Journal of Clinical Oncology×19
- Leukemia×12
- Michael W. Deininger
Medicine · University of Michigan
- Christopher Davis
Medicine · Indiana University
- Ravi Bhatia
Medicine · University of Michigan
- Taylor K. Johnson
Medicine · University of Michigan
- Xiaoling Xuei
Medicine · Indiana University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 25, 2026.
Claim or correct this profile